Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.41 |
| ▸ | CTSH | P09668 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292353 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL18328801 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL1783726 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL1783728 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL15756119 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL258985 | 1.00 | CTSK (0.56) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL8387889 | 0.99 | CTSK (0.57) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL8972183 | 0.99 | CTSK (0.57) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL8695376 | 0.99 | CTSK (0.57) | CTSKALDH1A1CTSLCTSBCTSH | |
| SCHEMBL9234715 | 0.93 | CTSK (0.52) | CTSKALDH1A1CTSLCTSBCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 657 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | claimed |
| WO-2024153744-A1 | AUTOPHAGY ACTIVATORS FOR THE TREATMENT OF RHABDOMYOLYSIS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-07-25 | — | — | WO | claimed |
| WO-2024150130-A2 | NECROSIS INHIBITOR | LINKGEVITY LIMITED (GB) | 2024-07-18 | — | — | WO | claimed |
| WO-2024118561-A2 | DYSREGULATION OF NEUROPROTEASOMES BY APOE ISOFORMS DRIVES ENDOGENOUS TAU AGGREGATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-06-06 | — | — | WO | claimed |
| EP-4313144-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | Angiex, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024018245-A1 | USE OF CALPAIN INHIBITORS FOR THE TREATMENT OF THE DIABETIC KIDNEY DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-01-25 | — | — | WO | claimed |
| CN-117355333-A | Combination comprising anti-TM 4SF1 antibody and immunotherapeutic agent and method of use thereof | 安吉克公司 | 2024-01-05 | — | — | CN | claimed |
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. | 2023-09-21 | — | — | US | claimed |
| CN-217763217-U | Road lighting and environmental monitoring integrated device | 河北润衡环境治理有限公司 | 2022-11-08 | — | — | CN | claimed |
| WO-2000007619-A1 | ALTERATION OF THE CELL CYCLE IN VIVO, AND PARTICULARLY FOR INDUCING APOPTOSIS OF TUMOR CELLS | ALFACELL CORPORATION (US) | 2000-02-17 | — | — | WO | claimed |
| WO-1999045974-A1 | PROTEASE INHIBITORS IN ABSORBENT ARTICLES | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-16 | — | — | WO | claimed |
| US-5942494-A | Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-08-24 | — | — | US | claimed |
| EP-0724429-B1 | COMPOSITION AND METHOD FOR DELIVERY OF DRUGS | ADVANCED RES & TECH INST (US) | 1999-07-07 | — | — | EP | claimed |
| WO-1999025830-A1 | TRANSCRIPTIONALLY REGULATED G PROTEIN-COUPLED RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-05-27 | — | — | WO | claimed |
| EP-0724429-A1 | COMPOSITION AND METHOD FOR DELIVERY OF DRUGS | INDIANA UNIVERSITY FOUNDATION (US) | 1996-08-07 | — | — | EP | claimed |
| EP-0652290-A1 | Method for regulation of NF-kB | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1995-05-10 | — | — | EP | claimed |
| US-5171217-A | Injecting drug carried on microparticles of biocompatible biodegradable polymer into vessel wall under directed pressure | INDIANA UNIVERSITY FOUNDATION (US) | 1992-12-15 | — | — | US | claimed |
| WO-1992015282-A2 | COMPOSITION AND METHOD FOR DELIVERY OF DRUGS | INDIANA UNIVERSITY FOUNDATION (US) | 1992-09-17 | — | — | WO | claimed |
| WO-1992013549-A1 | INHIBITION OF CELL PROLIFERATION BY HYDROPHOBIC PEPTIDES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-08-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | TM9SF4, TM9SF2, TM9SF3 | CTSK 1456/4885ALDH1A1 2644/4885CTSL 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.